D
Xenetic Biosciences, Inc.
XBIO
$2.52
-$0.07-2.70%
D
Sell
2/20/2025Upgraded
Xenetic Biosciences, Inc. (XBIO) was upgraded to D- from E+ on 2/20/2025 due to an increase in the total return index and volatility index.
Xenetic Biosciences, Inc. (XBIO) was upgraded to D- from E+ on 2/20/2025 due to an increase in the total return index and volatility index.
E
Sell
2/5/2025Downgrade
Xenetic Biosciences, Inc. (XBIO) was downgraded to E+ from D- on 2/5/2025 due to a decline in the volatility index.
Xenetic Biosciences, Inc. (XBIO) was downgraded to E+ from D- on 2/5/2025 due to a decline in the volatility index.
D
Sell
1/21/2025Upgraded
Xenetic Biosciences, Inc. (XBIO) was upgraded to D- from E+ on 1/21/2025 due to an increase in the volatility index.
Xenetic Biosciences, Inc. (XBIO) was upgraded to D- from E+ on 1/21/2025 due to an increase in the volatility index.
E
Sell
1/6/2025Downgrade
Xenetic Biosciences, Inc. (XBIO) was downgraded to E+ from D- on 1/6/2025 due to a decline in the solvency index and volatility index.
Xenetic Biosciences, Inc. (XBIO) was downgraded to E+ from D- on 1/6/2025 due to a decline in the solvency index and volatility index.
D
Sell
6/25/2024Upgraded
Xenetic Biosciences, Inc. (XBIO) was upgraded to D- from E+ on 6/25/2024 due to an increase in the total return index and volatility index.
Xenetic Biosciences, Inc. (XBIO) was upgraded to D- from E+ on 6/25/2024 due to an increase in the total return index and volatility index.
E
Sell
6/7/2024Downgrade
Xenetic Biosciences, Inc. (XBIO) was downgraded to E+ from D- on 6/7/2024 due to a noticeable decline in the growth index, volatility index and solvency index. Operating cash flow declined 46.19% from -$793 to -$1.16M, total revenue declined 23.99% from $672 to $510.8, and the quick ratio declined from 11.1 to 10.92.
Xenetic Biosciences, Inc. (XBIO) was downgraded to E+ from D- on 6/7/2024 due to a noticeable decline in the growth index, volatility index and solvency index. Operating cash flow declined 46.19% from -$793 to -$1.16M, total revenue declined 23.99% from $672 to $510.8, and the quick ratio declined from 11.1 to 10.92.
D
Sell
5/20/2024Upgraded
Xenetic Biosciences, Inc. (XBIO) was upgraded to D- from E+ on 5/20/2024 due to an increase in the volatility index.
Xenetic Biosciences, Inc. (XBIO) was upgraded to D- from E+ on 5/20/2024 due to an increase in the volatility index.
E
Sell
5/2/2024Downgrade
Xenetic Biosciences, Inc. (XBIO) was downgraded to E+ from D- on 5/2/2024 due to a decline in the volatility index and growth index.
Xenetic Biosciences, Inc. (XBIO) was downgraded to E+ from D- on 5/2/2024 due to a decline in the volatility index and growth index.
D
Sell
4/17/2024Upgraded
Xenetic Biosciences, Inc. (XBIO) was upgraded to D- from E+ on 4/17/2024 due to an increase in the total return index and volatility index.
Xenetic Biosciences, Inc. (XBIO) was upgraded to D- from E+ on 4/17/2024 due to an increase in the total return index and volatility index.
E
Sell
3/27/2024Downgrade
Xenetic Biosciences, Inc. (XBIO) was downgraded to E+ from D- on 3/27/2024 due to a decline in the volatility index, growth index and solvency index. Earnings per share declined from -$0.6887 to -$0.7658, and EBIT declined 9.51% from -$1.15M to -$1.26M.
Xenetic Biosciences, Inc. (XBIO) was downgraded to E+ from D- on 3/27/2024 due to a decline in the volatility index, growth index and solvency index. Earnings per share declined from -$0.6887 to -$0.7658, and EBIT declined 9.51% from -$1.15M to -$1.26M.
D
Sell
3/14/2024Upgraded
Xenetic Biosciences, Inc. (XBIO) was upgraded to D- from E+ on 3/14/2024 due to an increase in the volatility index and total return index.
Xenetic Biosciences, Inc. (XBIO) was upgraded to D- from E+ on 3/14/2024 due to an increase in the volatility index and total return index.
E
Sell
2/28/2024Downgrade
Xenetic Biosciences, Inc. (XBIO) was downgraded to E+ from D- on 2/28/2024 due to a decline in the volatility index.
Xenetic Biosciences, Inc. (XBIO) was downgraded to E+ from D- on 2/28/2024 due to a decline in the volatility index.
D
Sell
2/7/2024Upgraded
Xenetic Biosciences, Inc. (XBIO) was upgraded to D- from E+ on 2/7/2024 due to an increase in the volatility index.
Xenetic Biosciences, Inc. (XBIO) was upgraded to D- from E+ on 2/7/2024 due to an increase in the volatility index.
E
Sell
1/23/2024Downgrade
Xenetic Biosciences, Inc. (XBIO) was downgraded to E+ from D- on 1/23/2024 due to a noticeable decline in the growth index, volatility index and total return index. Total revenue declined 6.11% from $651 to $611.2.
Xenetic Biosciences, Inc. (XBIO) was downgraded to E+ from D- on 1/23/2024 due to a noticeable decline in the growth index, volatility index and total return index. Total revenue declined 6.11% from $651 to $611.2.
D
Sell
5/22/2023Upgraded
Xenetic Biosciences, Inc. (XBIO) was upgraded to D- from E+ on 5/22/2023 due to a major increase in the growth index, valuation index and solvency index. EBIT increased 41.46% from -$1.56M to -$915.2, earnings per share increased from -$0.9841 to -$0.6, and total revenue increased 24.39% from $487 to $605.8.
Xenetic Biosciences, Inc. (XBIO) was upgraded to D- from E+ on 5/22/2023 due to a major increase in the growth index, valuation index and solvency index. EBIT increased 41.46% from -$1.56M to -$915.2, earnings per share increased from -$0.9841 to -$0.6, and total revenue increased 24.39% from $487 to $605.8.
E
Sell
5/15/2023Downgrade
Xenetic Biosciences, Inc. (XBIO) was downgraded to E+ from D- on 5/15/2023 due to a decline in the valuation index and growth index. EBIT declined 84.39% from -$847.8 to -$1.56M, and earnings per share declined from -$0.0562 to -$0.0984.
Xenetic Biosciences, Inc. (XBIO) was downgraded to E+ from D- on 5/15/2023 due to a decline in the valuation index and growth index. EBIT declined 84.39% from -$847.8 to -$1.56M, and earnings per share declined from -$0.0562 to -$0.0984.
D
Sell
3/14/2023Downgrade
Xenetic Biosciences, Inc. (XBIO) was downgraded to D- from D on 03/14/2023.
Xenetic Biosciences, Inc. (XBIO) was downgraded to D- from D on 03/14/2023.
D
Sell
2/9/2023Upgraded
Xenetic Biosciences, Inc. (XBIO) was upgraded to D from E+ on 2/9/2023 due to an increase in the total return index.
Xenetic Biosciences, Inc. (XBIO) was upgraded to D from E+ on 2/9/2023 due to an increase in the total return index.
E
Sell
2/8/2023Downgrade
Xenetic Biosciences, Inc. (XBIO) was downgraded to E+ from D on 2/8/2023 due to a noticeable decline in the total return index, solvency index and volatility index.
Xenetic Biosciences, Inc. (XBIO) was downgraded to E+ from D on 2/8/2023 due to a noticeable decline in the total return index, solvency index and volatility index.
D
Sell
5/5/2022Upgraded
Xenetic Biosciences, Inc. (XBIO) was upgraded to D from D- on 5/5/2022 due to an increase in the total return index.
Xenetic Biosciences, Inc. (XBIO) was upgraded to D from D- on 5/5/2022 due to an increase in the total return index.
D
Sell
4/20/2022Downgrade
Xenetic Biosciences, Inc. (XBIO) was downgraded to D- from D on 4/20/2022 due to a major decline in the total return index and growth index. Operating cash flow declined 41.16% from -$1.03M to -$1.46M, EBIT declined 36.19% from -$1.38M to -$1.87M, and total revenue declined 4.78% from $349.3 to $332.6.
Xenetic Biosciences, Inc. (XBIO) was downgraded to D- from D on 4/20/2022 due to a major decline in the total return index and growth index. Operating cash flow declined 41.16% from -$1.03M to -$1.46M, EBIT declined 36.19% from -$1.38M to -$1.87M, and total revenue declined 4.78% from $349.3 to $332.6.
D
Sell
11/15/2021Upgraded
Xenetic Biosciences, Inc. (XBIO) was upgraded to D from D- on 11/15/2021.
Xenetic Biosciences, Inc. (XBIO) was upgraded to D from D- on 11/15/2021.
D
Sell
11/8/2021Downgrade
Xenetic Biosciences, Inc. (XBIO) was downgraded to D- from D on 11/8/2021 due to a decline in the volatility index.
Xenetic Biosciences, Inc. (XBIO) was downgraded to D- from D on 11/8/2021 due to a decline in the volatility index.
D
Sell
12/9/2020Upgraded
Xenetic Biosciences, Inc. (XBIO) was upgraded to D from D- on 12/9/2020 due to an increase in the volatility index and total return index.
Xenetic Biosciences, Inc. (XBIO) was upgraded to D from D- on 12/9/2020 due to an increase in the volatility index and total return index.
D
Sell
11/16/2020Downgrade
Xenetic Biosciences, Inc. (XBIO) was downgraded to D- from D on 11/16/2020 due to a large decline in the growth index, solvency index and valuation index. Earnings per share declined from -$0.1517 to -$1.2008, EBIT declined 28.38% from -$982.5 to -$1.26M, and the quick ratio declined from 10.25 to 8.95.
Xenetic Biosciences, Inc. (XBIO) was downgraded to D- from D on 11/16/2020 due to a large decline in the growth index, solvency index and valuation index. Earnings per share declined from -$0.1517 to -$1.2008, EBIT declined 28.38% from -$982.5 to -$1.26M, and the quick ratio declined from 10.25 to 8.95.
D
Sell
5/20/2020Upgraded
Xenetic Biosciences, Inc. (XBIO) was upgraded to D from D- on 5/20/2020 due to a major increase in the growth index and total return index. Total revenue increased 231.58% from $17.1 to $56.7, operating cash flow increased 40.36% from -$1.68M to -$1M, and earnings per share increased from -$0.2009 to -$0.19.
Xenetic Biosciences, Inc. (XBIO) was upgraded to D from D- on 5/20/2020 due to a major increase in the growth index and total return index. Total revenue increased 231.58% from $17.1 to $56.7, operating cash flow increased 40.36% from -$1.68M to -$1M, and earnings per share increased from -$0.2009 to -$0.19.
D
Sell
3/27/2020Upgraded
Xenetic Biosciences, Inc. (XBIO) was upgraded to D- from E+ on 3/27/2020 due to an increase in the growth index, solvency index and efficiency index. Earnings per share increased from -$2.6677 to -$0.2009, net income increased 86.85% from -$8.9M to -$1.17M, and EBIT increased 48.83% from -$4.56M to -$2.33M.
Xenetic Biosciences, Inc. (XBIO) was upgraded to D- from E+ on 3/27/2020 due to an increase in the growth index, solvency index and efficiency index. Earnings per share increased from -$2.6677 to -$0.2009, net income increased 86.85% from -$8.9M to -$1.17M, and EBIT increased 48.83% from -$4.56M to -$2.33M.
E
Sell
7/23/2019Downgrade
Xenetic Biosciences, Inc. (XBIO) was downgraded to E+ from D- on 7/23/2019 due to a decline in the total return index and volatility index.
Xenetic Biosciences, Inc. (XBIO) was downgraded to E+ from D- on 7/23/2019 due to a decline in the total return index and volatility index.
D
Sell
7/1/2019Upgraded
Xenetic Biosciences, Inc. (XBIO) was upgraded to D- from E+ on 7/1/2019 due to an increase in the volatility index and valuation index.
Xenetic Biosciences, Inc. (XBIO) was upgraded to D- from E+ on 7/1/2019 due to an increase in the volatility index and valuation index.
E
Sell
5/24/2019Downgrade
Xenetic Biosciences, Inc. (XBIO) was downgraded to E+ from D- on 5/24/2019 due to a decline in the total return index, solvency index and volatility index.
Xenetic Biosciences, Inc. (XBIO) was downgraded to E+ from D- on 5/24/2019 due to a decline in the total return index, solvency index and volatility index.
D
Sell
3/29/2019Downgrade
Xenetic Biosciences, Inc. (XBIO) was downgraded to D- from D on 3/29/2019 due to a noticeable decline in the growth index, efficiency index and total return index. Total capital declined 12.24% from $11.3M to $9.91M.
Xenetic Biosciences, Inc. (XBIO) was downgraded to D- from D on 3/29/2019 due to a noticeable decline in the growth index, efficiency index and total return index. Total capital declined 12.24% from $11.3M to $9.91M.
D
Sell
8/9/2018Upgraded
Xenetic Biosciences, Inc. (XBIO) was upgraded to D from D- on 8/9/2018 due to an increase in the total return index and valuation index.
Xenetic Biosciences, Inc. (XBIO) was upgraded to D from D- on 8/9/2018 due to an increase in the total return index and valuation index.
D
Sell
7/11/2018Downgrade
Xenetic Biosciences, Inc. (XBIO) was downgraded to D- from D on 7/11/2018 due to a decline in the volatility index and valuation index.
Xenetic Biosciences, Inc. (XBIO) was downgraded to D- from D on 7/11/2018 due to a decline in the volatility index and valuation index.
D
Sell
6/26/2018Upgraded
Xenetic Biosciences, Inc. (XBIO) was upgraded to D from D- on 6/26/2018 due to an increase in the volatility index.
Xenetic Biosciences, Inc. (XBIO) was upgraded to D from D- on 6/26/2018 due to an increase in the volatility index.
D
Sell
5/17/2018Downgrade
Xenetic Biosciences, Inc. (XBIO) was downgraded to D- from D on 5/17/2018 due to a substantial decline in the growth index, volatility index and valuation index. EBIT declined 141.26% from $4.43M to -$1.83M, earnings per share declined from $0.5099 to -$0.21, and operating cash flow declined 134.45% from $4.84M to -$1.67M.
Xenetic Biosciences, Inc. (XBIO) was downgraded to D- from D on 5/17/2018 due to a substantial decline in the growth index, volatility index and valuation index. EBIT declined 141.26% from $4.43M to -$1.83M, earnings per share declined from $0.5099 to -$0.21, and operating cash flow declined 134.45% from $4.84M to -$1.67M.
D
Sell
4/2/2018Upgraded
Xenetic Biosciences, Inc. (XBIO) was upgraded to D from D- on 4/2/2018 due to a large increase in the growth index and efficiency index. Total revenue increased 8,723.53% from $85 to $7.5M, operating cash flow increased 395.52% from -$1.64M to $4.84M, and EBIT increased 297.76% from -$2.24M to $4.43M.
Xenetic Biosciences, Inc. (XBIO) was upgraded to D from D- on 4/2/2018 due to a large increase in the growth index and efficiency index. Total revenue increased 8,723.53% from $85 to $7.5M, operating cash flow increased 395.52% from -$1.64M to $4.84M, and EBIT increased 297.76% from -$2.24M to $4.43M.
D
Sell
2/1/2018Downgrade
Xenetic Biosciences, Inc. (XBIO) was downgraded to D- from D on 2/1/2018 due to a decline in the volatility index.
Xenetic Biosciences, Inc. (XBIO) was downgraded to D- from D on 2/1/2018 due to a decline in the volatility index.
D
Sell
12/27/2017Upgraded
Xenetic Biosciences, Inc. (XBIO) was upgraded to D from D- on 12/27/2017 due to an increase in the volatility index.
Xenetic Biosciences, Inc. (XBIO) was upgraded to D from D- on 12/27/2017 due to an increase in the volatility index.
D
Sell
12/12/2017Downgrade
Xenetic Biosciences, Inc. (XBIO) was downgraded to D- from D on 12/12/2017 due to a decline in the volatility index.
Xenetic Biosciences, Inc. (XBIO) was downgraded to D- from D on 12/12/2017 due to a decline in the volatility index.
D
Sell
11/16/2017Upgraded
Xenetic Biosciences, Inc. (XBIO) was upgraded to D from D- on 11/16/2017 due to a large increase in the growth index, solvency index and efficiency index. EBIT increased 22.83% from -$2.9M to -$2.24M, net income increased 22.71% from -$2.92M to -$2.26M, and earnings per share increased from -$0.3353 to -$0.26.
Xenetic Biosciences, Inc. (XBIO) was upgraded to D from D- on 11/16/2017 due to a large increase in the growth index, solvency index and efficiency index. EBIT increased 22.83% from -$2.9M to -$2.24M, net income increased 22.71% from -$2.92M to -$2.26M, and earnings per share increased from -$0.3353 to -$0.26.
D
Sell
4/17/2017Upgraded
Xenetic Biosciences, Inc. (XBIO) was upgraded to D- from E+ on 4/17/2017 due to an increase in the growth index, total return index and volatility index.
Xenetic Biosciences, Inc. (XBIO) was upgraded to D- from E+ on 4/17/2017 due to an increase in the growth index, total return index and volatility index.
E
Sell
3/31/2017Downgrade
Xenetic Biosciences, Inc. (XBIO) was downgraded to E+ from D- on 3/31/2017 due to a noticeable decline in the growth index, total return index and efficiency index. EBIT declined 1,657.17% from -$2.25M to -$39.56M, operating cash flow declined 349.4% from -$1.03M to -$4.62M, and earnings per share declined from -$0.2751 to -$0.5338.
Xenetic Biosciences, Inc. (XBIO) was downgraded to E+ from D- on 3/31/2017 due to a noticeable decline in the growth index, total return index and efficiency index. EBIT declined 1,657.17% from -$2.25M to -$39.56M, operating cash flow declined 349.4% from -$1.03M to -$4.62M, and earnings per share declined from -$0.2751 to -$0.5338.
D
Sell
7/7/2016Upgraded
Xenetic Biosciences, Inc. (XBIO) was upgraded to D- from E+ on 7/7/2016 due to an increase in the valuation index and volatility index.
Xenetic Biosciences, Inc. (XBIO) was upgraded to D- from E+ on 7/7/2016 due to an increase in the valuation index and volatility index.
E
Sell
6/16/2016Downgrade
Xenetic Biosciences, Inc. (XBIOD) was downgraded to E+ from D- on 6/16/2016 due to a decline in the volatility index and total return index.
Xenetic Biosciences, Inc. (XBIOD) was downgraded to E+ from D- on 6/16/2016 due to a decline in the volatility index and total return index.
D
Sell
6/1/2016Upgraded
Xenetic Biosciences, Inc. (XBIO) was upgraded to D- from E+ on 6/1/2016 due to a noticeable increase in the growth index, volatility index and efficiency index. EBIT increased 31.21% from -$2.69M to -$1.85M, total capital increased 14.69% from $10.66M to $12.22M, and earnings per share increased from -$0.0253 to -$0.0236.
Xenetic Biosciences, Inc. (XBIO) was upgraded to D- from E+ on 6/1/2016 due to a noticeable increase in the growth index, volatility index and efficiency index. EBIT increased 31.21% from -$2.69M to -$1.85M, total capital increased 14.69% from $10.66M to $12.22M, and earnings per share increased from -$0.0253 to -$0.0236.
E
Sell
3/11/2016Downgrade
Xenetic Biosciences, Inc. (XBIO) was downgraded to E+ from D on 3/11/2016 due to a major decline in the solvency index, volatility index and valuation index. Debt to equity increased from 0.06 to 0.62.
Xenetic Biosciences, Inc. (XBIO) was downgraded to E+ from D on 3/11/2016 due to a major decline in the solvency index, volatility index and valuation index. Debt to equity increased from 0.06 to 0.62.
D
Sell
2/2/2015Upgraded
Xenetic Biosciences, Inc. (XBIO) was upgraded to D from D- on 2/2/2015 due to an increase in the valuation index.
Xenetic Biosciences, Inc. (XBIO) was upgraded to D from D- on 2/2/2015 due to an increase in the valuation index.
D
Sell
10/1/2014Upgraded
Xenetic Biosciences, Inc. (XBIO) was upgraded to D- from E on 10/1/2014 due to an increase in the growth index, solvency index and volatility index. EBIT increased 4.67% from -$2.49M to -$2.61M.
Xenetic Biosciences, Inc. (XBIO) was upgraded to D- from E on 10/1/2014 due to an increase in the growth index, solvency index and volatility index. EBIT increased 4.67% from -$2.49M to -$2.61M.
E
Sell
6/16/2014Upgraded
Xenetic Biosciences, Inc. (XBIO) was upgraded to E from E- on 6/16/2014 due to an increase in the total return index, valuation index and solvency index. The quick ratio increased from 1.42 to 4.11, and debt to equity declined from 0.05 to 0.03.
Xenetic Biosciences, Inc. (XBIO) was upgraded to E from E- on 6/16/2014 due to an increase in the total return index, valuation index and solvency index. The quick ratio increased from 1.42 to 4.11, and debt to equity declined from 0.05 to 0.03.
E
Sell
4/21/2014Upgraded
Xenetic Biosciences plc (XBIO) was upgraded to E- from on 4/21/2014 due to a significant increase in the solvency index, volatility index and growth index. Total revenue increased 38.75% from -$32 to -$44.4.
Xenetic Biosciences plc (XBIO) was upgraded to E- from on 4/21/2014 due to a significant increase in the solvency index, volatility index and growth index. Total revenue increased 38.75% from -$32 to -$44.4.
NASDAQ
04/04/2025 10:42AM Eastern
Quotes delayed
